切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (02) : 201 -204. doi: 10.3877/cma.j.issn.1674-3946.2020.02.027

所属专题: 文献

论著

TACE术联合RFA术对高危部位原发性肝癌的临床疗效分析
张强1, 李恒平1,()   
  1. 1. 441000 湖北襄阳,湖北医药学院附属襄阳市第一人民医院
  • 收稿日期:2019-02-09 出版日期:2020-04-26
  • 通信作者: 李恒平

Clinical analysis of TACE combined with RFA in treating primary liver cancers of high-risk sites

Qiang Zhang1, Hengping Li1,()   

  1. 1. Xiangyang No.1 People’s Hospital, Hubei University of Medicine Hubei, 441000, China
  • Received:2019-02-09 Published:2020-04-26
  • Corresponding author: Hengping Li
  • About author:
    Corresponding author: Li Hengping , Email:
引用本文:

张强, 李恒平. TACE术联合RFA术对高危部位原发性肝癌的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2020, 14(02): 201-204.

Qiang Zhang, Hengping Li. Clinical analysis of TACE combined with RFA in treating primary liver cancers of high-risk sites[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(02): 201-204.

目的

探讨经动脉栓塞术(TACE)联合射频消融术(RFA)对高危部位原发性肝癌的临床疗效。

方法

回顾性分析自2013年4月至2018年4月收治的100例高危部位原发性肝癌患者资料,根据不同疗法分为两组,每组50例。TACE组患者采用TACE术进行治疗,联合组患者采用TACE术联合RFA术进行治疗。数据采用SPSS18.0进行分析,两组患者近期疗效、1年内生存率和术后并发症采用χ2检验,两组患者的甲胎蛋白(AFP)和体力状况评分(KPS)指标采用(±s)表示,独立t检验,P<0.05差异有统计学意义。

结果

联合组患者近期疗效高于TACE组(P<0.05);联合组患者1年生存率为77.9%高于TACE组1年生存率54.6%(P<0.05);术前,两组患者的AFP数值和KPS数值对比,差异无统计学意义(P>0.05),术后,联合组患者的AFP数值低于TACE组(P<0.05),但KPS数值高于TACE组(P<0.05);联合组患者腹痛的不良反应率高于TACE组(P<0.05),但其他各项不良反应均低于TACE组(P<0.05)。

结论

TACE术联合RFA术对高危部位原发性肝癌的近期疗效比单纯TACE术要好,患者的生存期有所延长,联合术对不能实施手术治疗的原发性肝癌患者有着很好的应用价值,值得临床推广。

Objective

To investigate the clinical effect of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in the treatment of primary liver cancers of high-risk sites.

Methods

Clinical data of 100 patients with primary liver cancers of high-risk sites from April 2013 to April 2018 were analyzed retrospectively. According to different therapeutic treatments, 100 patients were divided into TACE group (50 cases) and Combined group (50 cases). Patients in TACE group received TACE, while patients in Combined group underwent both TACE and RFA. Statistical analysis were performed by using SPSS18.0 software. Count data such as 1-year survival rate, short-term outcome and postoperative complications were analyzed by using χ2 test. Measurement data such as AFP and KPS were represented as (±s) and were examined by using t test. A P value of < 0.05 was considered as statistical significant difference.

Results

Short-term curative effect in Combined group was significantly higher than that in TACE group (P<0.05), and the one-year survival rate of 77.9% in combined group was significantly higher than that 54.6% in TACE group (P<0.05). There was no significant difference between two groups in terms of AFP and KPS before operation (P>0.05). After operation, AFP in Combined group was much lower than that in TACE group (P<0.05), while KPS in Combined group was much higher than that in TACE group (P<0.05). The incidence of abdominal pain in Combined group was higher than that in TACE group (P<0.05), however other adverse reactions were lower than those in TACE group respectively (P<0.05).

Conclusion

TACE combined with RFA is better than TACE alone in the treatment of primary liver cancers of high-risk sites, with improved survival of the patients. The combined treatments have application value for patients with unresectable primary liver cancers, and it is worth of clinical promotion.

表1 100例原发性肝癌不同疗法两组患者一般资料比较(例)
表2 100例原发性肝癌不同疗法两组患者近期疗效比较[例(%)]
表3 100例原发性肝癌不同疗法两组患者术前术后AFP及KPS数值比较(±s)
表4 100例原发性肝癌不同疗法两组患者术后并发症情况比较[例(%)]
[1]
王健,佟小强,吕天石,等.肝动脉化疗栓塞术联合射频消融治疗肝内特殊部位恶性肿瘤[J].中国微创外科杂志,2016,37(1):9-12.
[2]
Gholamrezanezhad A,Mirpour S,Geschwind JF,et al.Evaluation of 70-150-μm doxorubicin-eluting beads for transcatheter arterial chemoembolization in the rabbit liver VX2 tumour model[J].Eur Radiol,2016,26(10):3474-3482.
[3]
高飞,庞志刚,韩斌,等.肝动脉化疗栓塞联合射频消融术治疗大肝癌的疗效及生存分析[J].介入放射学杂志,2016,25(4):316-319.
[4]
赵中伟,纪建松,邵国良,等.肝动脉化疗栓塞联合射频消融治疗包膜下肝癌的疗效和安全性[J].中华放射学杂志,2016,50(5):380-383.
[5]
Ako S,Nakamura S,Nouso K,et al.Transcatheter Arterial Chemoembolization to Reduce Size of Hepatocellular Carcinoma before Radiofrequency Ablation[J].Acta Medica Okayama,2018,72(1):47-52.
[6]
谢可平,邹嵩,曾艳,等.肝动脉栓塞联合射频消融术治疗肝癌的效果及护理配合[J].中华肿瘤防治杂志,2016,21(S1):331-332.
[7]
朱楠,鲁东,肖景坤,等.肝动脉化疗栓塞联合射频消融术治疗中晚期肝癌的疗效[J].中国介入影像与治疗学,2017,14(4):195-199.
[8]
Hashimoto S,Ogino H,Iwata H,et al.Proton Beam Therapy for Locally Recurrent Hepatocellular Carcinoma After Radiofrequency Ablation or Transcatheter Arterial Chemoembolization[J].International Journal of Radiation Oncologybiologyphysics,2017,99(2):S193-S194.
[9]
袁筑慧,王洋,李威.经皮射频消融术治疗外科切除术后复发性肝细胞癌疗效分析[J].中国癌症杂志,2017,27(12):959-963.
[10]
刘江伟,黄建钊,孙倩,等.射频消融术和手术治疗原发性肝癌对照分析[J].中国医学计算机成像杂志,2016,22(5):444-450.
[11]
陈兵,吴威.射频消融对原发性肝癌治疗评价及预后危险因素分析[J].实用放射学杂志,2016,32(10):1545-1548.
[12]
Kato K,Abe H,Ika M,et al.C-Arm Cone Beam Computed Tomography Guidance for Radiofrequency Ablation in Hepatocellular Carcinoma[J].Oncology,2017,92(3):142-152.
[13]
Zuo TY,Liu FY,Wang MQ,et al.TranscatheterArterialChemoembolizationCombinedwithSimultaneousComputedTomography-guidedRadiofrequencyAblationforLargeHepatocellularCarcinomas[J].Chin Med J(Engl),2017,130(22):2666-2673.
[14]
王军,彭磊,崔海宁,等.射频消融及手术治疗不同大小小肝癌的无瘤生存率及复发转移率[J].实用医学杂志,2016,32(17):2851-2853.
[15]
方良毅,陈晓明,金浩生,等.多层螺旋CT多平面重建技术在肝癌射频消融术中的应用[J].介入放射学杂志,2016,25(5):425-430.
[16]
Liu H,Wang ZG,Fu SY,et al.Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria[J].Br J Surg,2016,103(4):348-356.
[17]
肖飞,胡波,宋亚锋.射频消融对比手术切除治疗小肝癌的Meta分析[J].中华肿瘤防治杂志,2016,23(S2):321-322.
[18]
Lv N,Kong Y,Mu L,et al.Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial[J].Eur Radiol,2016,26(10):3492-3499.
[1] 王春荣, 陈姜, 喻晨. 循Glisson蒂鞘外解剖、Laennec膜入路腹腔镜解剖性左半肝切除术临床应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 37-40.
[2] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[3] 汤海琴, 郭秀枝, 朱晓素, 赵世娣. “隧道法”腹腔镜解剖性左半肝切除术的临床安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 674-677.
[4] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[5] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[6] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[7] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[8] 严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[9] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[10] 张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[11] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[12] 唐灿, 李向阳, 秦浩然, 李婧, 王天云, 柯阳, 朱红. 原发性肝脏神经内分泌肿瘤单中心12例诊治与疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 674-680.
[13] 张维志, 刘连新. 基于生物信息学分析IPO7在肝癌中的表达及意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 694-701.
[14] 陈安, 冯娟, 杨振宇, 杜锡林, 柏强善, 阴继凯, 臧莉, 鲁建国. 基于生物信息学分析CCN4在肝细胞癌中表达及其临床意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 702-707.
[15] 叶文涛, 吴忠均, 廖锐. 癌旁组织ALOX15表达与肝癌根治性切除术后预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 708-712.
阅读次数
全文


摘要